State of Alaska Department of Revenue Has $1.16 Million Stake in Certara, Inc. (NASDAQ:CERT)

State of Alaska Department of Revenue reduced its position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) by 40.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 117,549 shares of the company's stock after selling 79,691 shares during the period. State of Alaska Department of Revenue owned approximately 0.07% of Certara worth $1,163,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Certara by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 12,437,089 shares of the company's stock worth $132,455,000 after acquiring an additional 38,068 shares during the period. ArrowMark Colorado Holdings LLC boosted its position in shares of Certara by 164.2% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock valued at $66,171,000 after purchasing an additional 3,861,674 shares during the period. Teacher Retirement System of Texas boosted its position in shares of Certara by 13.9% in the 4th quarter. Teacher Retirement System of Texas now owns 4,557,951 shares of the company's stock valued at $48,542,000 after purchasing an additional 557,348 shares during the period. Massachusetts Financial Services Co. MA boosted its position in shares of Certara by 4.7% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 4,083,940 shares of the company's stock valued at $43,494,000 after purchasing an additional 182,042 shares during the period. Finally, Brown Brothers Harriman & Co. boosted its position in shares of Certara by 63.8% in the 4th quarter. Brown Brothers Harriman & Co. now owns 3,818,613 shares of the company's stock valued at $40,668,000 after purchasing an additional 1,487,998 shares during the period. 73.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. KeyCorp increased their price target on Certara from $15.00 to $18.00 and gave the company an "overweight" rating in a research report on Wednesday, April 16th. JMP Securities reiterated a "market perform" rating on shares of Certara in a research report on Tuesday, May 6th. Robert W. Baird increased their price target on Certara from $9.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, April 11th. Finally, Barclays upgraded Certara from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $11.00 to $14.00 in a research report on Thursday, May 8th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $15.67.

Certara Stock Down 0.4%

NASDAQ CERT traded down $0.04 during trading on Friday, reaching $11.38. 2,205,514 shares of the company's stock were exchanged, compared to its average volume of 1,434,128. Certara, Inc. has a fifty-two week low of $8.64 and a fifty-two week high of $16.93. The firm has a market capitalization of $1.85 billion, a PE ratio of -569.00 and a beta of 1.45. The company has a current ratio of 2.78, a quick ratio of 2.78 and a debt-to-equity ratio of 0.27. The company's fifty day simple moving average is $11.94 and its 200-day simple moving average is $11.85.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Monday, May 5th. The company reported $0.14 EPS for the quarter, topping analysts' consensus estimates of $0.10 by $0.04. Certara had a positive return on equity of 5.05% and a negative net margin of 0.67%. The firm had revenue of $106.00 million during the quarter, compared to analyst estimates of $104.44 million. During the same period last year, the company posted $0.10 EPS. The business's quarterly revenue was up 9.7% compared to the same quarter last year. Sell-side analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.